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Summary
Patients with chronic obstructive pulmonary disease (COPD) are often characterised by
a range of characteristic co-morbidities that interfere with their pulmonary disease.
In addition to a mere association with co-morbidities, a complex pathophysiological
interaction and mutual augmentation occurs between COPD and its co-morbidities that may
result in disease progression and increased morbidity and mortality. An interdisciplinary
approach is required both for diagnosis and treatment to target co-morbidities early in the
course of the disease. This review summarizes the current knowledge of the interaction
with cerebrovascular disease and endocrinological co-morbidities in COPD patients.
There is growing evidence that COPD is an independent risk factor for ischemic stroke,
increasing the risk about twofold. Stroke risk in COPD patients increases with the
severity of the disease as measured by the degree of airﬂow limitation. The presence
of cardiovascular risk factors is of particular importance for stroke prevention in COPD
patients. Endocrinological co-morbidities are also important and many are associated with
increased cardiovascular risk. Impaired glucose metabolism ranges from insulin resistance
to overt diabetes mellitus, which is a frequent ﬁnding and is associated with worse
outcome.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) reaches
beyond the lungs, resulting in many systemic manifestations.
Key mechanisms involved in the pathophysiology and
systemic manifestations are hypoxaemia, hypercapnia,
systemic inﬂammation, and neurohormonal activation.1,2 A
variety of co-morbidities in COPD patients inﬂuence the
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clinical presentation and patient outcomes.3 Until relatively
recently there was little attention paid in the literature
to co-morbidities in COPD. Most published reports on co-
morbidities focus on systemic inﬂammation, cancer, and
cardiovascular disease while the body of evidence on
cerebrovascular disease and glucose metabolism is much
less. Clearly, an interdisciplinary approach is warranted
in order to adequately target relevant risk factors and
pathophysiological cross-links that may traditionally be
considered as non-pulmonary medical issues. This review
will summarize the available evidence for cerebrovascular
and endocrinological complications and co-morbidities in
COPD to provide critical evaluation of current knowledge,
implications for clinical practice and to give guidance for
future research.
0954-6111$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
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Table 1
Mechanisms of increased stroke risk in patients with COPD.
Mechanism Underlying cause Reference(s)
↑ coagulation ↑ ﬁbrinogen concentration Pinol-Ripoll 200812
↑ thrombin-antithrombin complex level Sabit 201019
↑ prothrombin activation fragments 1 & 2 Sabit 201019
↑ plasminogen activator inhibitor-1 level Jiang 201020
↑ thrombocyte aggregation ↑ b-thromboglobulin concentration Cella 200123
↑ P-selectin level Davì 199724
↑ thromboxane biosynthesis
↑ endothelial dysfunction ↓ nitric oxide concentration Cella 200123
↑ thrombomodulin concentration Cella 200123
↓ ﬂow-mediated vasodilation Eickhoff 200821
↑ arterial stiffness Maclay 200922
↑ large artery atherosclerosis ↑ oxidative stress Fimognari 200817
↑ C-reactive protein levels
↑ small vessel occlusion ↑ prevalence of diabetes Feary 20108
? borderzone infarction ↓ lower arterial oxygen pressure & reduced cerebral blood ﬂow Miyamoto 2000,25 van Dijk 200426
Cerebrovascular disease
Stroke as a consequence of COPD
The growing prevalence of cardiovascular risk factors is an
increasing medical and socioeconomic problem in modern
society. Importantly, with improved medical care of acute
cardiovascular events and an increasingly aged society the
prevalence of chronic diseases will increase and contribute
to an increasing prevalence of co-morbidities such as COPD
and stroke. Various interrelated mechanisms contribute to
an increased stroke risk in COPD-patients. First, COPD and
stroke may co-exist as a result of shared risk factors.
The probability of cardiovascular disease is much higher
in COPD-patients. According to data from the American
National Health Interview Survey (NHIS; n = 18,342; aged
40 years) the odds ratio for cardiovascular disease was 2.7
(95%CI 2.3–3.2) for COPD-patients,4 including a higher risk
for established stroke risk factors like myocardial infarction
(OR 2.2 (95%CI 1.7–2.8)),5 congestive heart failure (OR 3.9
(95%CI 2.8–5.5))6 and cardiac arrhythmia (OR 2.4 (95%CI
2.0–2.8)).7 Similar results were reported from a large UK-
database (The Health Improvement Network, THIN), of
1,200,000 medical records from over 300 primary care
centres. In this study there was an OR of 5.0 (95%CI
4.9–5.8) for cardiovascular disease, and an OR of 2.0
(95%CI 2.0–2.1) for diabetes in physician-diagnosed COPD-
patients.8 A retrospective analysis of medical records from
Saskatchewan (Canada) revealed a signiﬁcantly higher rate
of myocardial infarction (OR 1.6, 95%CI 1.4–1.8), congestive
heart failure (OR 3.8, 95%CI 3.6–4.1) and cardiac arrhythmia
(OR 1.8, 95%CI 1.6–1.9) in COPD-patients.9 Subsequently,
patients with COPD are at risk of stroke due to large-artery
atherosclerosis, small-vessel occlusion and embolic stroke.
Furthermore, available data indicate, that COPD poses a
direct increased risk for stroke in addition to shared risk
factors for both diseases. According to THIN-data, COPD
increases the odds of having a stroke (including subarachnoid
and intracranial hemorrhage and transient ischemic attack
(TIA) by 3.3 (95%CI 3.2–3.5) or 2.8 (95%CI 2.6–3.0) for
ﬁrst-ever stroke, respectively8. In addition, the NHIS-data
indicated an OR of 1.5 (95%CI 1.1–2.1) for stroke in COPD-
patients4, which is in line with a report from the prospective
Atherosclerosis Risk in Communities (ARIC) study, which
reported an adjusted HR of 1.50 (95%CI 1.04–2.2) for stroke
in patients with or without asthma.10 In addition in the
Saskatchewan cohort, there was a signiﬁcantly higher rate
of stroke (OR 1.1 (95%CI 1.02–1.2)) in COPD-patients9.
A German case–control study (including 370 patients with
mild to moderate stroke as well as age- and gender-matched
controls) demonstrated an OR of 2.6 (95%CI 1.2–5.9) for
stroke in patients with self reported moderate to severe
chronic bronchitis (CB).11 Unfortunately, this study was
underpowered to detect independent associations between
CB-patients and TIA or hemorrhagic stroke. Finally, a Spanish
case–control study (including 393 stroke patients) revealed
an OR of 1.8 (95%CI 1.4–2.5) for stroke in patients with self-
reported CB.12
The mechanisms for the association between COPD and
stroke are not fully understood, however several possible
mechanisms have been proposed. First, COPD is a chronic
inﬂammatory condition with an association with acute and
chronic infections,13 and inﬂammation/infection is per se
a proven risk factor for ischemic stroke.14 Inﬂammation/
Infection promotes large-artery atherosclerosis15–17 and
induces a pro-coagulatory state leading to thrombus
formation and embolic stroke.18 In addition, there is
evidence for enhanced atherosclerosis, hypoxia-induced
systemic oxidative stress17 and hypercoagulability,19,20 en-
dothelial dysfunction,20,21 arterial stiffness22 and increased
thrombocyte aggregation in COPD-patients23,24 – Table 1.
COPD is associated with overactivity of the sympathetic
nervous system and of the renin–angiotensin–aldosterone
system,27 which seems to be of particular importance in
this regard. Similar pathophysiological changes have been
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described for obstructive sleep apnoea,28 which is a known
risk factor of ischemic stroke.29 Despite the fact that the
frequency of obstructive sleep apnoea in COPD-patients is
similar to the general population, both disorders (“overlap
syndrome”) coexist in about 1% of all male adults, leading
to more pronounced nocturnal oxygen desaturation28 Also
for muscle tissue wasting and structural muscle changes
an overlap between stroke30 and COPD31,32 may exist.
Whether this myopenia33 is disease speciﬁc or results from
a common and/or additive catabolic overdrive34 remains to
be established.
Prevalence and incidence of stroke in patients
with COPD
Data from the NHIS4 indicate that 8.0% of all COPD-patients
(n = 958; mean age 63 years, 56% female) had a history
of stroke before enrolment. In this study the ethnical
background or the body mass index had no impact on
stroke risk in COPD-patients. By contrast gender was a
signiﬁcant confounder as stroke was more prevalent in men
than in women in the NHIS (OR 1.3 (95%CI: 1.1–1.7))4.
A similar gender-related stroke rate was reported in the THIN
data set.8 As expected, multivariable analysis of THIN-data
identiﬁed advanced age and smoking as additional stroke
risk factors in patients with COPD. However, during a median
follow-up of 895 days the incidence of ﬁrst-ever stroke was
highest in the younger age groups (HR 3.44 (95%CI 0.85–
13.8) and HR 2.21 (95%CI 1.3–3.6) for 35–44 or 45–54 years,
respectively).8
The stroke risk is also dependent on the disease severity
of COPD as suggested by the majority of observational
studies.35 However, only two studies35,36 corrected for
relevant confounders such as smoking, socioeconomic status
or diabetes. According to both studies, there was an almost
linear association between the decrease of forced expiratory
volume and ischemic stroke risk.
White matter lesions and silent stroke in
patients with COPD
White matter lesions are frequently detected in older
individuals37 as a consequence of cerebral arteriosclerosis,
hypoperfusion and focal ischemia.38 One might argue
that lower arterial oxygen tensions in COPD-patients may
augment white matter lesions. However, hypoxia without
additional ischemia did not cause brain necrosis in rats,
although hypoxia exacerbates ischemic damage.25
There are a limited number of observational studies
that have focused on brain MRI ﬁndings in patients with
COPD. The Rotterdam Scan study reported MRI-detected
silent strokes in about 20% of all 1077 non-demented
participants aged 60–90 years.37 A subgroup analysis focused
on 73 individuals with COPD26). Compared to participants
without COPD those with COPD had signiﬁcantly more severe
white matter lesions within the periventricular arterial
border zone, indicating that cerebral hypoperfusion might
play a role. Similar results were obtained for participants
with lower arterial oxygen saturation, which suggests
that hypoxemia is an important factor. There was no
relevant increase in subcortical lesions or lacunar strokes
in participants with COPD. Interestingly, the smoking status
of COPD-patients did not affect this association.
A subgroup analysis of the Atherosclerosis Risk in
Communities Study assessed lung function and brain MRI
in 1917 patients (aged 55–72 years, 50% African-Americans)
without a history of a stroke.38 Compared with the highest
FEV-quartile, patients in the lowest quartile had a threefold
higher rate of clinically silent stroke and a twofold higher
risk of white matter disease. Within the lowest FEV-quartile
20% had a silent stroke and 16% had white matter lesions.
Furthermore, the results of the Cardiovascular Health Study
emphasise the link between the severity of COPD and
white matter lesions.39 However, the association between
lower FEV1 and the extent of white matter lesions was
not signiﬁcant after adjustment for gender and history of
smoking.
In the Cardiovascular Health Study, about one third of all
3301 participants without a history of stroke (aged 65 years
and older) had a clinically silent stroke according to MRI
ﬁndings. Unfortunately, MRI data for patients with known
COPD were not reported.
A case–control study with small numbers of cases (18
COPD-patients, 9 age- and gender-matched controls) using
MRI and MRI spectroscopy did not ﬁnd relevant structural
alterations (such as hippocampal atrophy or enhanced
white matter lesions) or signiﬁcant neurochemical brain
changes.40 According to a recent meta-analysis, white
matter lesions generally predict an increased risk of
dementia, stroke, and death.41 Comparable data for white
matter lesions in COPD-patients are missing so far. Whether
white matter lesions are linked to cognitive impairment
in patients with COPD is not known at present. However,
up to 77% of all patients with COPD and hypoxemia
experience neuropsychological changes including decreased
attention, loss of memory, diminished psychomotor speed
and decreased executive function,42 ﬁndings similar to
those described for patients with chronic heart failure.43
Moreover, existing cognitive impairment obviously predicts
mortality in COPD-patients.42
Stroke and COPD: Implications for mortality
Recent evidence indicates a higher (cardiovascular) mor-
tality after ischemic stroke in patients with COPD9. About
4% of all COPD-related deaths within the “Towards a
Revolution in COPD Health” (TORCH) study were caused
by stroke.44 In addition, a history of in-hospital stroke
was independently associated with a signiﬁcantly higher in
hospital mortality in a cohort of 398 patients hospitalized
for COPD exacerbations.45 Moreover, the risk of stroke-
associated death has been shown to be inversely related
to FEV.46
Acute stroke therapy and stroke prevention in
COPD-patients
Currently, there is no convincing evidence that provision
of oxygen is effective after acute stroke in humans.47
However, animal data support the concept of normobaric
hyperoxia for neuroprotection after acute stroke.48 The
current European Stroke Organisation (ESO) guidelines state
that “treatment of hypoxia is believed to be important
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in individuals with extensive brain stem or hemispheric
stroke, seizure activity, or complications such as pneumonia,
cardiac failure, pulmonary embolism, or exacerbation of
COPD”.49
Available evidence on the prevention of strokes in COPD-
patients is limited. According to guidelines the presence
of COPD is not relevant for primary or secondary stroke
prevention.49 Therefore, stroke prevention in COPD-patients
has to be tailored according to their cardiovascular risk
proﬁle. Anticoagulation is only indicated in COPD-patients
with atrial ﬁbrillation and not in those with sinus rhythm.50
Apart from smoking cessation, treatment of additional
cardiovascular risk factors is of particular importance in
COPD-patients.
Clinical implications
COPD is an independent risk factor for stroke, increasing
the stroke risk by around twofold. Moreover, stroke-
related mortality rates are considerably higher in COPD-
patients. Stroke prevention in patients with COPD has to be
tailored according to the existing cardiovascular risk proﬁle.
Prospective clinical studies are needed to test whether
optimal treatment of COPD might reduce the burden of
stroke.
Endocrinological issues in COPD
Chronic diseases often induce (over-)activation of several
pathways, which disturb endocrinological homeostasis. A
range of mechanisms including systemic inﬂammation,
neurohormones, blood gas disturbances, and glucocorticoid
administration contribute to anabolic/catabolic imbalance
and impaired whole body metabolism in COPD. COPD
is associated in some patients with muscle wasting and
weakness, and thus many reports focused on anabolic
hormones, thyroid function, and adrenal gland.51,52 Together
with neurohormonal activation2,27,53 these factors promote
catabolic dominance and hence the development of
cachexia and it is in such patients that the most severe
endocrinological disturbances occur. Although of primary
interest in general healthcare, glucose metabolism and the
metabolic syndrome have been less investigated in COPD.
Deﬁnitions
Type II diabetes mellitus (DM) is a typical disease of modern
society such that it results from an unhealthy lifestyle.54,55
Current diagnostic criteria primarily address blood glucose
levels (fasting blood glucose, oral glucose tolerance test;
HbA1c) but in the clinical practice we identify only the tip of
the iceberg with respect to disturbed glucose metabolism.56
Insulin resistance (IR) is the underlying pathophysiological
principle of type II DM and is deﬁned as an impaired
physiological response of glucose utilisation to a given
insulin concentration. IR may initially be overcome by
increased beta cell activity to increase endogenous insulin
production. Accordingly, IR precedes clinically manifest
DM by years, if not decades. Insulin is a hormone
with pleiotropic actions that may be affected differently
depending on whether there is reduced activity (if resistance
applies) or increased stimulation (if hyperinsulinaemia
provokes increased signalling) with consequent adverse
effects on the cardiovascular, muscular, and metabolic
systems. In COPD, an increased cardiovascular mortality risk
seems most relevant and is associated with impaired glucose
metabolism.3 Screening for insulin resistance in clinical
practice is done by an evaluation of metabolic syndrome
criteria (Table 2). There is some dispute in the scientiﬁc
Table 2
Metabolic syndrome deﬁnition criteria.
NCEP ATP III IDF
3 out of 5 waist + 2 out of 4
Waist circumference
Males 102 cm 94 cm
Females 88 cm 80 cm
Fasting glucosea b 5.6mmol/L 5.6mmol/L
High density lipoproteinsb
Males <1mmol/L <1mmol/L
Females <1.3mmol/L <1.3mmol/L
Triglyceridesb 1.7mmol/L 1.7mmol/L
Blood pressureb 130/85mmHg 130/85mmHg
NCEP ATP III: National Cholesterol Education Program Adult
Treatment Pannel III; IDF: International Diabetes Federation.
a either above cut-off or established diabetes mellitus or speciﬁc
treatment.
b either above cut-off or speciﬁc treatment.
community over these criteria57–59 and it remains unclear
whether they apply for patients with established chronic
conditions, e.g. COPD or chronic heart failure.60 While
the features of the metabolic syndrome give an indirect
indication of the presence of IR, direct measurement is
less well established in routine clinical practice. A range
of methods for quantiﬁcation of IR are used, mainly in
research studies that include single-point estimates or
serial assessments of glucose/insulin in response to glucose
or insulin stress. The Homeostasis Model Assessment of
Insulin Resistance (HOMA-IR) is the most simple method
which requires measurements of fasting plasma glucose and
insulin. Comparable methods are Fasting Insulin Resistance
Index (FIRI) and the QUick Insulin Check Index (QUICKI). More
complex methods such as minimal modelling techniques
require repeated blood sampling for glucose and insulin
determination after intravenous application of glucose
or insulin.61 The Gold standard test is the euglycemic
hyperinsulinemic clamp technique, which measures glucose
turnover in a euglycemic steady state during high-level
insulin infusion.
Insulin resistance and the metabolic syndrome
In chronic diseases, several mechanisms can induce the
resistance of peripheral tissues, particularly muscle and
fat, to insulin. In relation to COPD cigarette smoking also
induces chronic systemic inﬂammation and oxidative stress
which increases risk of insulin resistance. An association
between systemic inﬂammation and insulin resistance was
demonstrated in a study that compared 56 patients with
COPD and 29 healthy subjects.62 HOMA-IR was signiﬁcantly
higher in COPD patients (1.68±2.58 vs 1.13±2.02, p = 0.032)
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and correlated with serum levels of interleukin-6 (r = 0.276,
p = 0.039) and tumour necrosis factor a (r = 0.351, p = 0.008).
A signiﬁcantly higher HOMA-IR was reported in another
study63 which compared 55 patients with COPD and 25
healthy controls (p = 0.001). Other reports found no such
association but they included fewer patients, used oral
glucose tolerance test or did not measure glucose uptake
by stable isotopes.64
The deﬁnition of the metabolic syndrome is based on
different criteria, which cluster around insulin resistance.
In 200 patients with established chronic bronchitis or COPD,
the prevalence of the metabolic syndrome was 47.5% and
decreased with increasing severity of COPD. The presence
of the metabolic syndrome was associated with increased
levels of hs-CRP and interleukin-6 levels, independent of
lung function impairment.65 A population based survey in
China detected airﬂow obstruction in 6.7% of 7358 adults
and 20% of those complied with International Diabetes
Federation metabolic syndrome criteria.66 The prevalence
is very likely underestimated because these criteria need
to be adjusted for Chinese population. More important,
however, is the ﬁnding that the adjusted risk of metabolic
syndrome was higher in those with airﬂow obstruction than
in those without (odds ratio 1.47, 95% conﬁdence interval
(CI) 1.12–1.92). When analysing the individual components
of the metabolic syndrome, only central obesity (adjusted
for body mass index) was signiﬁcantly associated with airﬂow
obstruction (odds ratio 1.43; 95% conﬁdence interval 1.09–
1.88). In summary of available evidence, the metabolic
syndrome is common in COPD, may in part explain the
increased risk of cardiovascular diseases in COPD, and should
be actively screened for and managed in clinical practice.
Diabetes mellitus
Whilst information on insulin resistance and its relevance
in COPD remains scarce, there are more data available for
DM. Notably, as IR precedes frank DM by several years,
the pathophysiologic mechanisms discussed above are active
long before DM is clinically recognised in COPD patients.
The use of systemic but not of inhaled glucocorticoids in
COPD is associated with higher risk of developing diabetes.67
The overall prevalence of DM in COPD is estimated to
be 10–14%.52 Whether COPD promotes development of DM
is controversial. No such association was found in the
Framingham Heart Study68 and the National Health and
Nutrition Examination Survey.69 By contrast, an analysis of
5498 patients with COPD (530 in GOLD stage III/IV) showed
increasing prevalence of DM with increasing GOLD stage
(10.1% in I vs 14.5% in III/IV, odds ratio for GOLD III/IV vs
I: 1.5 (95% conﬁdence interval 1.1–1.9)). Additionally, there
was a higher risk for hospitalization and death in COPD
patients with concomitant DM.70 Similar associations were
found during hospitalization for exacerbation of COPD.71 An
analysis of 172 patients with exacerbations reported that DM
occurred in 22% of patients and tended to increase mortality
(adjusted hazard ratio 1.93, 95% conﬁdence interval 0.43–
8.64).
Management
Conventional treatment of impaired glucose metabolism
primarily focuses on increased insulin dose rather than
insulin effectiveness. The most commonly used oral
pharmacological antidiabetic agents act as promotors of
endogenous insulin secretion whilst insulin is available as for
parenteral or nasal treatment.72 Metformin is another oral
antidiabetic agent which serves as an insulin sensitizer and
has the potential to reduce insulin resistance. Preliminary
data from a group of 61 patients with COPD and DM suggest
that in addition to their effects on glucose metabolism,
insulin sensitizers have the potential to improve pulmonary
function.73 Several interventions with potential outcome
beneﬁt in patients with COPD could also improve glucose
metabolism through demonstrated ancillary effects. Several
of these, like exercise training, testosterone, and beta
blockers, have been shown to reduce insulin resistance,
likely through their actions in skeletal muscle and fat
tissue.
Clinical implications
Active screening, primarily for sub clinical diabetes, and
timely management is warranted in COPD patients. Patients
with COPD are regularly exposed to the medical system,
either during stable phases of the disease in the outpatient
clinic or in exacerbations requiring hospital admission.
Both scenarios provide an opportunity to perform simple,
inexpensive, and mostly reliable tests for the presence
of endocrinological disorders. Because of established or
potential prognostic implications, tests could include fasting
blood glucose, oral glucose tolerance test, lipid and thyroid
hormone proﬁle. Although cardiovascular disease, DM, and
other co-morbidities are established prognostic risk factor in
COPD, there are no evidence based management guidelines
for COPD patients with co-morbidities.1,2 Currently it seems
appropriate to consult co-morbidity speciﬁc guidelines.
Muscle wasting and cachexia are not uncommon and are
associated with reverse epidemiology. Based on previous
experience in COPD and other chronic disease, some
parameters like body size74 or lipid proﬁle75 may be
particularly important and should be considered to guide
management.
Future research
There is a need for good epidemiological data on the
prevalence and incidence of cerebrovascular disease and
endocrinological disturbances in patients with COPD. Large-
scale multicenter prospective observational surveys are of
utmost importance in this regard. The Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints
(ECLIPSE)76 included 2164 clinically stable COPD patients,
337 smokers with normal lung function and 245 never
smokers. This database has a wealth of information and
is expected to serve as basis for detailed analyses in
this ﬁeld. We should also make use of the existing
patient databases, both in hospitalized and ambulatory
patients. Due to selection bias, analyses of randomized
trials are likely to be less relevant for clinical practice
as they reﬂect only selected populations, often without
the relevant co-morbidities discussed here. Initial analyses
should include simple measures that could be implemented
during 5-minute clinical consultation. Body size, routine
laboratory measures, electrocardiogram, and different
questionnaires have attractive cost-beneﬁt ratios and could
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provide relevant information on co-morbidities on a short
notice.
Many patients with COPD die out of hospitals thus
determination of cause of death remains extremely
difﬁcult.77 Sudden cardiac death, cerebrovascular incidents,
and respiratory failure may be most important causes of
death3 and some patients are likely to enter the medical
system via specialized emergency rooms. Data Inquiry from
stroke and acute coronary syndrome registries should be the
ﬁrst step to determine prevalence of acute events.
Although there is paucity of adequate epidemiological
data, we should now consider interventional trials to address
the targeted management of co-morbidities in COPD.2 The
authors ﬁrmly believe the time for adequately designed and
performed (pilot) trials has come and some are already
ongoing. We look forward to future reports to provide
additional insight into the epidemiology and management
of the somewhat neglected co-morbidities in patients with
COPD.
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